RESEARCH AND INNOVATION

Concept Foundation’s Research and Innovation team identifies, develops and evaluates new and neglected high potential sexual and reproductive health (SRH) medicines and technologies.

We scan and review the field to identify SRH products that are likely to be safe and effective and in parallel reduce inequities in our efforts to achieve Universal Health Coverage.

Photo Credit: Joni Kabana

rESEARCH AND INNOVATION

Concept Foundation’s Research and Innovation team identifies, develops and evaluates new and neglected high potential sexual and reproductive health (SRH) medicines and technologies.

We scan and review the field to identify SRH products that are likely to be safe and effective and in parallel reduce inequities in our efforts to achieve Universal Health Coverage.

Photo Credit: Joni Kabana

Basic and clinical research

  • We evaluate the benefits and harms of existing and new interventions
  • We develop new interventions for which there is a market need
    • New treatments
    • Diagnostics
    • Point-of-care tests
  • We use modern technologies to improve drug stability

Innovation

  • We perform landscape analysis of pipeline and marketed products
    • Contraception
    • Safe Medical Abortion
    • Maternal Health
  • We identify gaps in treatment options and other needs in maternal and reproductive health
  • We search for, and evaluate, new promising innovations

For questions and collaborations, please contact the R&D Programme Manager

OUR CURRENT FOCUS

ACCELERATING INNOVATION FOR MOTHERS (AIM)

In partnership with the Bill & Melinda Gates Foundation, Concept Foundation is engaging with key stakeholders in the pharmaceutical industry and public health field to assess the interest in establishing a Research Consortium including donors, manufacturers, procurers, academia and consumer organizations for new innovations in maternal health.

Concept Foundation will establish an understanding of the current state of the field of maternal health medicines development, by reviewing literature and interviewing key individuals, opinion-leaders from different stakeholder groups. In addition, the key drivers, challenges, and failures in Maternal Health will be identified. Policy Cures Research, known for their G-FINDER analysis, will conduct a comprehensive pipeline analysis of the history of maternal health drug development in the past 15-20 years.

The main scope of the AIM project are the following conditions:  preterm labor/ birth, preeclampsia/ eclampsia, impaired fetal growth, intrapartum fetal distress, and postpartum hemorrhage (PPH).

EARLY MENSTRUAL INDUCTION

Emergency contraception offers an effective solution in cases of unprotected intercourse. Emergency contraceptive pills and intrauterine device (IUD) provide a reliable option when taken within 3-5 days. However, after missing this 3-5 day window, women need to wait for expected menses and must take a pregnancy test to confirm pregnancy before being able to take the appropriate course of action from the options available.  

We aim to identify a new option that induces menses, and which can be used >5 days following unprotected intercourse.

CF is leading this project in collaboration with WHO HRP, CEMAG Care (France) and Chulalongkorn University  (Thailand).

PPH FIRST RESPONSE BUNDLE

An implementation research project to evaluate the impact of the first response PPH treatment bundle on substantive health outcomes.

The PPH first response bundle includes the administration of oxytocin (OXY), tranexamic acid (TXA), uterine massage and fluids.

The clinical study will take place in numerous health facilities in Kenya, Nigeria, Tanzania, South Africa and Sri Lanka.

CF will identify, select and evaluate the quality of the OXY and TXA products used in the facilities.

CF is conducting this project in a collaboration with the University of Birmingham (UK) and Monash University (Australia).

OUR RESEARCH APPROACH

Concept Foundation is mandated to work on quality-assured reproductive health medicines and technologies.

 

Between 2010 and 2020, CF conducted quality assessments of a large range of essential reproductive health medicines through our work within the Quality of Reproductive Health Medicines Programme (QuRHM) and the UN Commission for Life Saving Commodities. We continue to work on field collection of medicines and conduct testing with our partner laboratories.

Our second approach is to identify new and existing but inadequately evaluated and partly forgotten medicines. We believe that there should be more research and innovation to develop solutions for pregnancy-specific conditions like pre-eclampsia/eclampsia, preterm labour and birth, and obstetric haemorrhage. Similarly, we are working to improve contraceptive and pregnancy termination options through innovative approaches.

We are working on exploring and potentially expanding self-care for sexual and reproductive health medicines and technologies by conducting landscaping and systematic reviews. Our research approach is collaborative. We work closely with HRP/WHO, Birmingham University, UK, Monash University Institute of Pharmaceutical Sciences and the Burnet Institute, Australia and other partner organizations globally.